Nasdaq

Eicosapentaenoic Acid (EPA) Levels From VASCEPA® (Icosapent Ethyl) in REDUCE-IT® Strongly Correlated with Cardiovascular Outcomes

DUBLIN, Ireland and BRIDGEWATER, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that data presented by Deepak L. Bhatt ...
Medscape

STRENGTH Trial Questions CV Benefit of High-Dose Omega-3s

Questions about the cardiovascular benefit of omega-3 fatty acids and the high-dose eicosapentaenoic acid (EPA) product, icosapent ethyl (Vascepa, Amarin), have resurfaced with the presentation and ...
Medscape

MARINE: Ethyl-EPA Reduces Triglyceride Levels Without Raising LDL Cholesterol

November 30, 2010 (Dublin, Ireland and Mystic, Connecticut) — Ethyl eicosapentaenoic acid (EPA), a semisynthetic derivative of omega-3 fatty acids, significantly lowers triglyceride levels in patients ...
Healio

Icosapent ethyl appropriate to use to reduce CV risk, despite pending questions

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Findings of cardiovascular benefit with icosapent ethyl treatment from the REDUCE-IT trial have ...
Seeking Alpha

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic ...

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN) today announced that new supported and/or funded research on the clinical impact of VASCEPA ® ...
The American Journal of Managed Care

REDUCE-IT: Serum EPA Levels Hold Key to Vascepa's Dramatic CV Benefits

Higher levels of the omega-3 fatty acid eicosapentaenoic acid (EPA) found in the blood appear to explain why icosapent ethyl drives down the risk of a cardiovascular (CV) event, according to findings ...
Healio

Icosapent Ethyl Topic Review

Icosapent ethyl is a prescription-grade derivative of the omega-3 fatty acid eicosapentaenoic acid, a component of fish oil. Icosapent ethyl may be used for the management of severe ...
Seeking Alpha

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at ...

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT ® ...
Business Insider

New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a ...

DUBLIN and BRIDGEWATER, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today ...
Monthly Prescribing Reference

Case Series Describes Use of Icosapent Ethyl for COVID-19 Pneumonia

The authors described the cases of 3 patients with moderate to severe COVID-19 pneumonia who were treated with 2g of icosapent ethyl administered twice daily via a nasogastric tube. The use of ...
FierceBiotech

Amarin Receives Special Protocol Assessment Agreement from the FDA for Phase 3 Trial in Mixed Dyslipidemia

DUBLIN--(BUSINESS WIRE)--Amarin Corporation plc (NASDAQ: AMRN) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) ...
Business Insider

Eicosapentaenoic Acid (EPA) Levels From VASCEPA® (Icosapent Ethyl) in REDUCE-IT® Strongly Correlated with Cardiovascular Outcomes

Serum EPA Levels Showed Approximately 400% Increase Following Administration of VASCEPA High EPA Levels Associated with Substantial Reductions in Multiple Cardiovascular Endpoints Including Heart ...